PsiOxus wins Best Emerging UK biotech fundraiser at the OBN awards
OBN’s Annual Awards Dinner, last night celebrated the achievements and major success stories in biotech, medtech and diagnostics over the past year at a black tie event at The Ashmolean Museum, Oxford. The Awards sought to highlight the many achievements of the UK’s bioscience sector in raising funds, executing deals and supporting innovation, as well as the addition of two new awards for 2012 to recognise the “Highest Impact Investor” and the “Best Pharma BD&L Team”.
PsiOxus Therapeutics, Best Biotech Fundraiser
Award Presented by Pivotal Scientific
In July 2012, PsiOxus Therapeutics announced its closing of a Series B round of equity financing totalling £22 million, including investments from investors Imperial Innovations Invesco Perpetual, SR One and Lundbeckfond Ventures. The financing round will enable PsiOxus to advance the clinical development of ColoAd1, a systemically available oncolytic vaccine for the treatment of colorectal cancer.